177 related articles for article (PubMed ID: 32847130)
1. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Romaniello D; Marrocco I; Belugali Nataraj N; Ferrer I; Drago-Garcia D; Vaknin I; Oren R; Lindzen M; Ghosh S; Kreitman M; Kittel JC; Gaborit N; Bergado Baez G; Sanchez B; Eilam R; Pikarsky E; Paz-Ares L; Yarden Y
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847130
[TBL] [Abstract][Full Text] [Related]
2. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
Yonesaka K; Takegawa N; Watanabe S; Haratani K; Kawakami H; Sakai K; Chiba Y; Maeda N; Kagari T; Hirotani K; Nishio K; Nakagawa K
Oncogene; 2019 Feb; 38(9):1398-1409. PubMed ID: 30302022
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
4. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
5. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
[TBL] [Abstract][Full Text] [Related]
6. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
7. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
8. Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
Verma N; Müller AK; Kothari C; Panayotopoulou E; Kedan A; Selitrennik M; Mills GB; Nguyen LK; Shin S; Karn T; Holtrich U; Lev S
Cancer Res; 2017 Jan; 77(1):86-99. PubMed ID: 27793840
[TBL] [Abstract][Full Text] [Related]
9. Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
Lyu H; Han A; Polsdofer E; Liu S; Liu B
Acta Pharm Sin B; 2018 Jul; 8(4):503-510. PubMed ID: 30109175
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2
Yu X; Ghamande S; Liu H; Xue L; Zhao S; Tan W; Zhao L; Tang SC; Wu D; Korkaya H; Maihle NJ; Liu HY
Mol Ther Nucleic Acids; 2018 Mar; 10():317-330. PubMed ID: 29499944
[TBL] [Abstract][Full Text] [Related]
12. siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells.
Yuan HH; Yang YN; Zhou JH; Li YJ; Wang LY; Qin JW; Liu T; Li ZZ; Zhou QX; Wei XL; Zhang TT; Huang P; Zhang WJ; Liu L; Du XX; Han Y
Oncotarget; 2017 Aug; 8(32):52584-52593. PubMed ID: 28881753
[TBL] [Abstract][Full Text] [Related]
13. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
14. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
[TBL] [Abstract][Full Text] [Related]
15. HER3/ErbB3, an emerging cancer therapeutic target.
Zhang N; Chang Y; Rios A; An Z
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
[TBL] [Abstract][Full Text] [Related]
16. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
17. Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.
Wehrenberg-Klee E; Turker NS; Heidari P; Larimer B; Juric D; Baselga J; Scaltriti M; Mahmood U
J Nucl Med; 2016 Sep; 57(9):1413-9. PubMed ID: 27081168
[TBL] [Abstract][Full Text] [Related]
18. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment.
Liu X; Liu S; Lyu H; Riker AI; Zhang Y; Liu B
Biol Proced Online; 2019; 21():5. PubMed ID: 30930695
[TBL] [Abstract][Full Text] [Related]
19. Examination of HER3 targeting in cancer using monoclonal antibodies.
Gaborit N; Abdul-Hai A; Mancini M; Lindzen M; Lavi S; Leitner O; Mounier L; Chentouf M; Dunoyer S; Ghosh M; Larbouret C; Chardès T; Bazin H; Pèlegrin A; Sela M; Yarden Y
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):839-44. PubMed ID: 25564668
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
